RSS
 Add News     Print  
Article List
New drug to treat Kuwaitis suffering from ‘Hepatitis C’ Blood Bank works in 2 shifts: Dr Reem

KUWAIT CITY, July 3: Consultant Gastroenterologist and Liver Specialist and Head of Internal Medicine Department at Jahra Hospital Dr Bader Al-Enezi has declared that Kuwaitis who suffer from Hepatitis C will soon be treated with a new medicine in Kuwait after a long wait, reports Al- Rai daily.

In a press statement, Dr Al- Enezi explained that Kuwaiti patients who suffer from Hepatitis C are currently undergoing treatment with the use of common traditional medicines such as Interferon and Ribavirin which usually takes a year or more for effect. He indicated that some patients are not cured within this period because of which they have to start the medical treatment all over again. He revealed that the common medicines for treating Hepatitis C have severe side effects such as damage to liver, cancer or even death.

Dr Al-Enezi said the World Health Organization has recommended the use of the new drug which will soon be available in Kuwait, adding that the new medicine is compatible to the genes generally seen in Kuwaiti citizens, which is why its success rate is expected to be 100 percent. He indicated that the new drug will be in the form of pills that should be taken orally on a daily basis for about three months for effect.

Meanwhile, Director of Blood Transfusion Department Dr Reem Al-Rawdhan announced that the headquarters of Blood Bank in Jabriya and its branches will be open everyday except on Fridays while on Saturdays, it will open only in the evenings during the month of Ramadan, reports Al- Seyassah daily. She explained that the Blood Bank will work in two shifts — 8 am to 2 pm and from 8 pm to 1 am. Regarding the blood donation centers at Amiri, Adan and Jahra hospitals, Dr Al- Rawdhan explained that they will operate from 9 am to 1 pm during the weekdays while on Sundays and Tuesdays, they will be open in the evening from 8 pm to 2 am.

Read By: 3760
Comments: 0
Rated:

Comments
You must login to add comments ...
About Us   |   RSS   |   Contact Us   |   Feedback   |   Advertise With Us